%20(3).png){kind=small}
![TFD [LOGO] (10).png](https://static.wixstatic.com/media/bea252_c1775b2fb69c4411abe5f0d27e15b130~mv2.png/v1/crop/x_150,y_143,w_1221,h_1193/fill/w_179,h_176,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/TFD%20%5BLOGO%5D%20(10).png)
RUSSIA TURNS TO CHINESE FIRMS TO MANUFACTURE SPUTNIK VACCINE
- By The Financial District
- May 3, 2021
- 2 min read
Russia is turning to multiple Chinese firms to manufacture the Sputnik V coronavirus vaccine in an effort to speed up production as demand soars for its shot, Huizhong Wu and Daria Litvinova reported for the Associated Press [AP].
Russia has announced three deals totaling 260 million doses with Chinese vaccine companies in recent weeks. It’s a decision that could mean quicker access to a shot for countries in Latin America, the Middle East, and Africa that have ordered Russia’s vaccine, as the US and the European Union focus mainly on domestic vaccination needs.
RDIF said in April it would produce 100 million doses in collaboration with Hualan Biological Bacterin Inc., in addition to an earlier deal announced in March for 60 million doses with Shenzhen Yuanxin Gene tech Co.
The two deals are in addition to a deal announced last November with Tibet Rhodiola Pharmaceutical Holding Co, which had paid $9 million to manufacture and sell the Sputnik V vaccine in China. RDIF said in April the terms of the deal were for 100 million doses with a subsidiary company belonging to Tibet Rhodiola.
Earlier criticism about Russia’s vaccine has been largely quieted by data published in the British medical journal The Lancet that said large-scale testing showed it to be safe, with an efficacy rate of 91%.
Yet, experts have questioned whether Russia can fulfill its pledge to countries across the world. While pledging hundreds of millions of doses, it has only delivered a fraction.
Kremlin spokesman Dmitry Peskov has said demand for Sputnik V significantly exceeds Russia’s domestic production capacity. To boost production, the Russian Direct Investment Fund [RDIF], which bankrolled Sputnik V, has signed agreements with drug makers in other countries, such as India, South Korea, Brazil, Serbia, Turkey, Italy, and others.
There are few indications, however, that manufacturers abroad, except for those in Belarus and Kazakhstan, have made any large amounts of the vaccine so far. Airfinity, a London-based science analytics company, estimates Russia agreed to supply some 630 million doses of Sputnik V to over 100 countries, with only 11.5 million doses exported so far.
